ABSTRACT
Objective: To investigate the therapeutic effect and related mechanism of Shenling Baizhu San on 3% dextran sulfate sodium (DSS)-induced ulcerative colitis (UC) mice. Method: Sixty male SPF C57BL/6 mice were randomly divided into control group, salazosulfapyridine (SASP, 0.52 g·kg-1), and low, medium and high-dose (31.2, 15.6, 7.8 g·kg-1) Shenling Baizhu San groups. Except for the control group, mice in the other groups were given distilled water containing 3% dextran sulfate sodium salt for a week to establish UC models. The drug was administered once a day for 14 days. The normal group and the model group were administered with 0.9%physiological saline at 20 mL·kg-1. The mice's body weight, fecal traits, and occult blood were observed daily, and the disease activity index (DAI) was scored. After the end of the administration, the blood was collected, mice colons were collected, weighed and measured for length, and pathological sections were prepared. Enzyme-linked immunosorbent assay (ELISA) kit was used to detect the serum levels of interleukin-18 (IL-18) and IL-1β in mice; htoxylin eosin (HE) and alixin blue/schiff periodic acid shiff(AB/PAS) staining were used to observe the pathological changes of colon tissues; Western blot was used to detect the colon tissue of mice nucleotide binding oligomerization domain-like receptor 3 (NLPR3), NLPR6 protein expression levels. Result: Compared with the normal group, the DAI score of the model group was increased (PPβ content increased (PPPβ concentration was decreased (PPPPConclusion: Shenling Baizhu San has the effect in treating DSS-induced UC mice, which may be related to the regulation of NLRP3, NLRP6 protein and related inflammatory factors, so as to reduce intestinal inflammation and alleviate intestinal mucosal damage.